local_hospital

Casa Di Cura Macchiarella S.p.A.

Address
Viale Regina Margherita 25, 90138 Palermo, Italy

Casa Di Cura Macchiarella S.p.A. - Oncology Research Center

Casa Di Cura Macchiarella S.p.A. is a specialized oncology research facility dedicated to advancing multimodal cancer treatment approaches. The center demonstrates expertise in combining novel pharmacological interventions with established radiation and chemotherapy protocols, focusing on optimizing treatment outcomes for gastrointestinal and urological malignancies.

  • Locally advanced rectal cancer with neoadjuvant combination therapies
  • Intermediate risk prostate cancer with ultra-hypofractionated radiotherapy
  • Integration of metabolic agents (aspirin and metformin) in oncologic treatment protocols

The center's research portfolio includes innovative approaches such as ultra-hypofractionated radiotherapy combined with hormonal agents for prostate cancer, and the evaluation of aspirin and metformin as adjunctive therapies during neoadjuvant induction chemotherapy and chemoradiotherapy for rectal cancer. These trials demonstrate a commitment to exploring how repurposed medications and optimized radiation schedules can improve pathological response rates and biochemical outcomes in solid tumor management.

Site Overview

assignment
8
connected trials
corporate_fare
5
sponsors
science
19
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
1
Trials started 6–12 months ago
8
Total trials linked
Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 3 therapeutic areas and 15 of 19 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
7
Sponsors (total)
5
Active sponsors
5

Sponsor Network

Top 5 by active trials.

lock +4 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +1 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 566 other sites in Italy

description
Trial volume
8
Outperforms 65% of sites
public
Therapeutic diversity
3areas
Outperforms 57% of sites
groups
Sponsor diversity
5sponsors
Outperforms 61% of sites

Therapeutic Area Benchmark — Italy

Select a therapeutic area to compare against other sites in Italy.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Italy

Market Share

Country: Italy

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Casa Di Cura Macchiarella S.p.A.

lock Showing 1 of 8 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A phase II, open label, multicenter trial investigating Irinotecan plus cetuximab rechallenge compared with trifluridine/tipiracil plus bevacizumab as third line treatment in circulating tumor DNA molecularly selected metastatic colorectal cancer: the ROMANCE-GOIM trialGruppo Oncologico Dell'Italia MeridionalePhase IIRecruitingMar 2026

IMP list

lock Showing 1 of 19 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Bevacizumab4Unknown2019-01-032026-03-11

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.